Edwards Lifesciences Corporation (EW) stock surged 5.4% in pre-market trading on Wednesday, driven by the company's impressive fourth quarter 2024 financial results and positive outlook for 2025. The medical device maker reported a 9% year-over-year increase in total sales to $1.39 billion for Q4 2024, fueled by robust growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment.

A key highlight was the strong performance of the TMTT business, which saw sales jump 77% year-over-year to $352 million for the full year 2024. This segment, which includes the PASCAL and EVOQUE systems, is expected to continue driving growth, with the company forecasting TMTT sales in the range of $500 million to $530 million for 2025.

While the company's flagship Transcatheter Aortic Valve Replacement (TAVR) segment experienced slower growth, with sales increasing 6% year-over-year to $4.1 billion in 2024, Edwards Lifesciences remains optimistic about the segment's prospects. The company cited compelling early TAVR data that could lead to more patients seeking treatment, positioning the segment for multi-year growth.